Nav: Home

Parkinson's Disease Funding Analyzer launched on Journal of Parkinson's Disease website

March 31, 2016

The Journal of Parkinson's Disease (JPD) is proud to announce the launch of the Parkinson's Disease Funding Analyzer (PDFA) on the JPD website. It is a free service that is part of a new suite of online features that have been designed to serve the needs of the Parkinson's disease (PD) research community.

PDFA presents in-depth data on 114 funders from 40 countries including all of the European Union, Australia, Canada, Ireland, Qatar, the United Kingdom, and the United States.

"This is a unique and remarkable tool that will be very valuable to everyone doing Parkinson's research," explained JPD's Editor-in-Chief Patrik Brundin, MD, PhD, Van Andel Research Institute. "It is becoming increasingly important to know more about the funding landscape and about who is working on what project so effective collaborations can be sought out."

Working with development partner ÜberResearch, a solutions and services company focused on the specific needs of science funders, PDFA includes all funding related to PD drawn from ÜberResearch's extensive grant database of more than $940 billion of funded research, representing more than 2 million projects from 200 funders like the National Institutes of Health and the National Science Foundation in the U.S. and the Wellcome Trust and U.K. Research Councils in the U.K.

PDFA allows users to easily locate funding related to PD and analyze funding streams and trends. Further, it facilitates a better understanding of research organizations' funding portfolios and the funding patterns of specific funders, both of which are critical when developing grant applications. For example, users can conduct line-of-investigation queries (e.g., alpha-synuclein, L-Dopa, transplantation) to look for funding trends and to see which investigators in which countries have been the most successful in obtaining funding in a given area of PD research. New funding information will be added to the PDFA on an ongoing basis.

"We invite all PD researchers to register at http://www.journalofparkinsonsdisease.com/funding for this valuable service, which we are pleased to make available at no charge," added Dr. Brundin. Registration not only enbles users to access the PDFA, but also use other features on the site.
-end-


IOS Press

Related Disease Articles:

Contact sports associated with Lewy body disease, Parkinson's disease symptoms, dementia
There is mounting evidence that repetitive head impacts from contact sports and other exposures are associated with the neurodegenerative disease chronic traumatic encephalopathy (CTE) and dementia.
In kidney disease patients, illicit drug use linked with disease progression and death
Among individuals with chronic kidney disease, hard illicit drug use was associated with higher risks of kidney disease progression and early death.
Parkinson's disease among patients with inflammatory bowel disease
Patients with inflammatory bowel disease appeared more likely than patients without the disorder to develop Parkinson's disease, while anti-tumor necrosis factor therapy for inflammatory bowel disease was associated with reduced incidence of Parkinson's in a new study that analyzed administrative claims data for more than 170 million patients.
Despite reductions in infectious disease mortality in US, diarrheal disease deaths on the rise
Deaths from infectious diseases have declined overall in the United States over the past three decades.
Defects on regulators of disease-causing proteins can cause neurological disease
Mutations in human PUMILIO1, a gene that regulates Ataxin1 production, cause conditions similar to spinocerebellar ataxia type 1 (SCA1).
Diabetes drug shows potential as disease-modifying therapy for Parkinson's disease
A drug commonly used to treat diabetes may have disease-modifying potential to treat Parkinson's disease, a new UCL-led study in The Lancet suggests, paving the way for further research to define its efficacy and safety.
Findings support role of vascular disease in development of Alzheimer's disease
Among adults who entered a study more than 25 years ago, an increasing number of midlife vascular risk factors, such as obesity, high blood pressure, diabetes, high cholesterol and smoking, were associated with elevated levels of brain amyloid (protein fragments linked to Alzheimer's disease) later in life, according to a study published by JAMA.
Dietary factors associated with substantial proportion of deaths from heart disease, stroke, and disease
Nearly half of all deaths due to heart disease, stroke, and type 2 diabetes in the US in 2012 were associated with suboptimal consumption of certain dietary factors, according to a study appearing in the March 7 issue of JAMA.
Study links changes in oral microbiome with metabolic disease/risk for dental disease
A team of scientists from The Forsyth Institute and the Dasman Diabetes Institute in Kuwait have found that metabolic diseases, which are characterized by high blood pressure, high blood sugar, and obesity -- leads to changes in oral bacteria and puts people with the disease at a greater risk for poor oral health.
Fatty liver disease contributes to cardiovascular disease and vice versa
For the first time, researchers have shown that a bi-directional relationship exists between fatty liver disease and cardiovascular disease.
More Disease News and Disease Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.